** Shares of clinical-stage biopharmaceutical firm Radiopharm Theranostics RAD.AX rise as much as 21.7% to A$0.028, their highest since Dec. 16
** Co inks co-development deal to develop biopharmaceuticals with Massachusetts-based Lantheus LNTH.O in Australia
** Deal includes basket clinical trial targeting multiple solid tumours
** Co to receive up to $2 mln in milestone payments upon achieving key objectives, with the LNTH footing all costs
** Including session's moves, stock trims YTD losses to 64.9% as of 2340 GMT
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.